Conference Coverage

Cultural humility required to optimize treatment of eczema patients with skin of color


 

AT SPD 2022

Follicular, nummular eczema

In her clinical experience, the most common clinical variants of AD in patients with skin of color is follicular eczema. “Examine the patient, apply your hand to the affected area, and you can feel the papules beneath your fingertips,” she advised.

“That’s what I teach my residents and medical students,” she said. “If you are looking for erythema to seal your diagnosis of AD, it may not happen. You may see more of a violaceous hue and sometimes you may not find it at all, depending on the patient’s skin tone. If I find an area of normal appearing skin and then look back at the area of active skin disease, I go back and forth until I’m able to train my eye to be able to see those violaceous and erythematous hues more easily.”

Nummular eczema can also be a challenge in AD patients with skin of color.

“I like to listen to buzz words,” Dr. Heath said. “If a parent says, ‘my child has been diagnosed with ringworm multiple times,’ I zoom in on that. We know that kids can get tinea corporis, but usually not multiple times. I ask about all the things that can be associated with AD, and often we do see these nummular plaques on the skin and do some education about that. I also talk to their pediatrician or send information to that person so that they can be aware that nummular eczema is a form of AD.”

She noted that AD of the scalp may be confused with tinea capitis, especially in young Black children with moderate to severe AD. In her experience, triamcinolone 0.1% ointment works well for AD of the scalp.

She concluded her presentation by noting that there is no easy solution to treating AD in young patients with skin of color. “It’s way more than just eczema. We can help people see AD in a different way. My goal is to see the value in challenging ourselves to understand the impact of what happens outside of the exam room on these patients.”

Dr. Heath disclosed that she has served as a consultant for several pharmaceutical companies, including Regeneron, Janssen, Arcutis, Johnson and Johnson, Cassiopea, and Lilly.

Pages

Recommended Reading

Adolescents and children with moderate-to-severe atopic dermatitis benefit from dupilumab
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Abrocitinib improves clinical scores in IGA nonresponders
MDedge Dermatology
Atopic dermatitis: Improvement in disease severity and skin barrier function with dupilumab
MDedge Dermatology
Atopic dermatitis: Upadacitinib-induced acne does not pose a significant safety risk
MDedge Dermatology
Difamilast shows promise as long-term therapeutic option for atopic dermatitis
MDedge Dermatology
Identifying factors associated with AD severity
MDedge Dermatology
Pediatric atopic dermatitis: Food allergy common but AD rarely triggered by food
MDedge Dermatology
Pediatric atopic dermatitis: Food allergy common but AD rarely triggered by food
MDedge Dermatology
Exposure to antibiotics in early life not linked to atopic dermatitis onset in childhood or adolescence
MDedge Dermatology
Atopic dermatitis and infectious cutaneous disorders: What is the link?
MDedge Dermatology